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OBJECTIVES The antiarrhythmic efficacies of the competitive angiotensin II (AII) antagonist losartan,
losartan’s more potent noncompetitive AII antagonist human metabolite EXP3174 and the
angiotensin-converting enzyme inhibitor captopril were assessed in a canine model of recent
myocardial infarction.
BACKGROUND Multiple hemodynamic and electrophysiologic effects of AII may contribute to cardiac
electrical instability. In the recent Losartan Heart Failure Study, Evaluation of Losartan in
the Elderly (ELITE), a 722-patient trial primarily designed to assess effects on renal function,
an unexpected survival benefit was observed with losartan compared with captopril, with the
lower mortality using losartan primarily confined to a reduction in sudden cardiac death.
METHODS Intravenous losartan (1 mg/kg 1 0.03 mg/kg/min), EXP3174 (0.1 mg/kg 1 0.01 mg/kg/
min), captopril (1 mg/kg 1 0.5 mg/kg/h) or vehicle were infused in anesthetized dogs with
recent (8.1 6 0.4 days) anterior myocardial infarction. Electrolytic injury of the left circumflex
coronary artery to induce thrombotic occlusion and posterolateral ischemia was initiated 1 h
after the start of treatment.
RESULTS Losartan, EXP3174 and captopril elevated plasma renin activities and comparably and
significantly reduced mean arterial pressure. No significant electrocardiographic or cardiac
electrophysiologic effects were noted with any treatment. Incidences of acute posterolateral
ischemia-induced lethal arrhythmias were: vehicle, 7/9 (77%); losartan, 6/8 (75%); EXP3174,
2/8 (25%; p , 0.05 vs. vehicle control); captopril, 7/10 (70%). There were no among-group
differences in time to onset of acute posterolateral ischemia or underlying anterior infarct size.
CONCLUSIONS EXP3174, but not losartan nor captopril, reduced the incidence of lethal ischemic ventricular
arrhythmia in this preparation. The antiarrhythmic efficacy of EXP3174 may be due to an
attenuation of deleterious effects of local cardiac AII formed during acute myocardial ischemia or,
alternatively, a non-AII-related activity specific to EXP3174. These findings suggest that in
humans, metabolic conversion of losartan to EXP3174 may afford antiarrhythmic protection.
(J Am Coll Cardiol 1999;34:876–84) © 1999 by the American College of Cardiology
Angiotensin-converting enzyme (ACE) inhibitors signifi-
cantly reduce mortality in patients with chronic symptom-
atic heart failure and in survivors of myocardial infarction
with left ventricular dysfunction (1–5). Early trials attrib-
uted the survival benefit of ACE inhibitors predominantly
to a retardation of hemodynamic deterioration (1–3). Some
recent trials have suggested a significant reduction in sud-
den, potentially arrhythmic death (5,6); however, sudden
cardiac death still remains the most common mode of death
in heart failure patients treated with ACE inhibitors (7).
The classification of the exact mode of death in heart failure
patients is complex. Sudden death in heart failure patients
often is preceded by a severe worsening in hemodynamic
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status, and in the absence of direct documentation, a clear
association between ventricular arrhythmias and sudden
death is not possible. Therefore, whether or not ACE
inhibitors afford survival benefit via antiarrhythmic protec-
tion remains uncertain (5,6,8-10). Further, clinical as well as
preclinical in vivo studies have failed to demonstrate a
consistent effect of ACE inhibitors on the frequency of
ventricular arrhythmia (9).
Selective angiotensin II (AII) antagonists recently have
become available for therapeutic use, and offer the potential
of more specific and complete blockade of the deleterious
actions of AII (11). Recently, the Losartan Heart Failure
Study (Evaluation of Losartan in the Elderly [ELITE])
compared therapy with the prototype AII antagonist losar-
tan with that of the ACE inhibitor captopril in patients
with chronic symptomatic heart failure, a patient group in
which ACE inhibitors including captopril have demon-
strated a significant survival benefit (12). ELITE was a
722-patient trial primarily designed to assess effects on renal
function. Although no difference was observed in renal
function between treatment groups and hemodynamic sta-
tus improved comparably in both treatment groups, an
unexpected survival benefit was observed in the losartan
group compared with the captopril group, with the lower
mortality in the losartan group largely confined to a reduc-
tion in sudden cardiac death (12).
Few preclinical studies have assessed the antiarrhythmic
potential of losartan (13–15). No preclinical studies to date
have provided a direct comparison of the antiarrhythmic
actions of the competitive AII antagonist losartan, losartan’s
more potent noncompetitive AII antagonist human metab-
olite EXP3174 and an ACE inhibitor in vivo. Accordingly,
the present study was designed to compare the antiarrhyth-
mic efficacies of losartan, EXP3174 and the ACE inhibitor
captopril in a canine model of recent myocardial infarction.
In this experimental model, the occurrence of thromboti-
cally induced acute posterolateral myocardial ischemia in the
setting of anterior infarction results in a high incidence of
sudden lethal ventricular arrhythmias, primarily ventricular
fibrillation (16,17). In these studies, losartan, EXP3174 and
captopril were administered intravenously starting 1 h be-
fore the acute ischemic triggering event at dosages eliciting
significant elevations in plasma renin activity in order to
assess their acute antiarrhythmic potentials. The use of the
dog as a test species permitted the comparison of the
antiarrhythmic activities of losartan and EXP3174 in the
virtual absence of metabolic conversion.
METHODS
All procedures related to the use of animals in these studies
were reviewed and approved by the Institutional Animal
Care and Use Committee at Merck Research Laboratories
at West Point and conform with the Guide for the Care and
Use of Laboratory Animals (Institute of Laboratory Animal
Resources, Commission on Life Sciences, National Re-
search Council, 1996). The preparation and use of the
canine model of recent anterior myocardial infarction in
which lethal ventricular arrhythmias are precipitated by
acute, thrombotically induced posterolateral myocardial isch-
emia was described originally by Patterson et al. (16).
Modifications of this preparation as used in the present
study have been described (17) and are summarized below.
Surgical preparation. Male or female purpose-bred mon-
grel dogs (6.7 to 11.5 kg; 8.8 6 0.2 kg; total n 5 35) were
preanesthetized with sodium thiamylal (5 mg/kg IV [intra-
venous]) and general anesthesia was induced with isoflu-
rane. A left thoracotomy was performed in the fourth
intercostal space, the pericardium incised and the heart
suspended in a pericardial cradle. Anterior myocardial
infarction was produced by a 2-h occlusion of the left
anterior descending coronary artery followed by reperfusion.
Surgical incisions were closed, and the animals were allowed
to recover.
Experimental protocol, electrophysiologic testing and
acute posterolateral myocardial ischemia. Animals were
studied at 5 to 14 (8.1 6 0.4) days after surgically induced
anterior myocardial infarction. Postinfarction dogs were
anesthetized with alpha chloralose (80 to 100 mg/kg IV),
and were ventilated with room air. Systemic arterial pressure
was monitored via the cannulated left common carotid
artery, and the right femoral vein was isolated and cannu-
lated for test compound administration. The heart was
reexposed via a left thoracotomy, and was suspended in a
pericardial cradle. A bipolar electrode was sutured to the left
atrial appendage for atrial pacing, and one bipolar plunge
electrode per zone was sutured into the infarcted anterior
region (infarct zone [IZ]) and into the noninfarcted pos-
terolateral region of the left ventricle (noninfarct zone
[NZ]) for the measurement of ventricular excitation thresh-
olds and refractory periods. Lead II electrocardiogram was
monitored continuously. After stabilization of the prepara-
tion, the following baseline parameters were measured:
sinus heart rate, mean arterial pressure, electrocardiographic
intervals including a rate-corrected QTc interval [QTc 5
(QT ms)/=(R 2 R s)], a paced QT interval determined
during 2.5-Hz atrial pacing, NZ and IZ ventricular excita-
tion thresholds (2-ms pulse duration, 300-ms coupling
interval) during 2.5-Hz atrial pacing and NZ and IZ
Abbreviations and Acronyms
ACE 5 angiotensin-converting enzyme
AI 5 angiotensin I
AII 5 angiotensin II
ANOVA 5 analysis of variance
ELITE 5 Evaluation of Losartan in the Elderly
IZ 5 infarct zone
LCX 5 left circumflex
NZ 5 noninfarct zone
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ventricular relative and effective refractory periods (2-ms
pulse duration at 23 and 103 ventricular excitation thresh-
olds, respectively) during 2.5-Hz atrial pacing.
Immediately after baseline assessment, animals were en-
tered in a randomized, blinded fashion into one of the
following four treatment groups: losartan potassium salt,
1 mg/kg IV bolus 1 0.03 mg/kg/min continuous IV
infusion in saline vehicle (n 5 8); EXP3174 HCl salt,
0.1 mg/kg IV bolus 1 0.01 mg/kg/min continuous IV
infusion in 50% PEG/D5W vehicle (n 5 8); captopril,
1 mg/kg IV bolus 1 0.5 mg/kg/h continuous IV infusion in
saline vehicle (n 5 10); and vehicle controls (total n 5 9)
comprised of matched volume bolus 1 continuous IV
infusion subgroups of saline (n 5 4) and PEG/D5W (n 5
5) vehicles. All doses of test agents reflect amounts of free
base compound. Dosing regimens for losartan, EXP3174
and captopril were based on previously published studies of
these agents in dogs: losartan (18,19); EXP3174 (18,20);
captopril (18,20–22). Before the initiation of treatment, and
at 1, 2 and 4 h into the IV treatment infusions, blood
samples were obtained for the measurement of plasma renin
activity in all four treatment groups (GammaCoat [125I]
Plasma Renin Activity Radioimmunoassay Kit; Incstar
Corp., Stillwater, Minnesota) to confirm that the losartan,
EXP3174 and captopril dosing regimens were pharmaco-
dynamically active. Blood samples from the losartan and
EXP3174 groups also were analyzed by HPLC with fluo-
rescence detection (23) for the simultaneous determination
of losartan and EXP3174 plasma concentrations in order to
assess the extent of metabolic conversion of losartan to
EXP3174.
At 1 h after the initiation of IV treatment infusion, heart
rate, blood pressure, electrocardiographic and cardiac elec-
trophysiologic parameters were redetermined. Immediately
thereafter, the tip of a silver wire electrode was inserted
through the wall and into the lumen of the proximal left
circumflex (LCX) coronary artery. An anodal current of
200 mA was applied to the intimal surface of the coronary
artery via this electrode, producing intimal injury, thrombus
formation and ultimately acute posterolateral myocardial
ischemia. Upon the development of lethal ischemic arrhyth-
mias or at 3 h after the onset of acute posterolateral
myocardial ischemia, the hearts were excised and wet
thrombus mass in the LCX coronary artery determined.
Anterior myocardial infarct size was determined by cutting
the heart into 1-cm-thick transverse sections, which then
were incubated in 0.4% triphenyltetrazolium chloride solu-
tion. Reaction with triphenyltetrazolium forms a red pre-
cipitate in viable tissue, whereas infarcted tissue remains
pale. Infarct size was quantitated gravimetrically and was
expressed as a percentage of total left ventricle. Note that
continuous IV treatment infusions of losartan, EXP3174,
captopril and vehicle continued throughout the period of
LCX intimal injury and ensuing posterolateral myocardial
ischemia.
Statistical analysis. Data were expressed as mean 6 SEM.
Treatment effects on heart rate, mean arterial pressure,
electrocardiographic and electrophysiologic parameters were
analyzed using a two-way analysis of variance (ANOVA)
comparing within treatment groups by repeated measure as
well as among all treatment groups. If the two-way
ANOVA indicated a significant change in a parameter
among treatment groups, a two-tailed paired Student t test
was used to detect significant differences within groups.
Among-group differences in time to onset of acute postero-
lateral myocardial ischemia, LCX coronary artery thrombus
mass and underlying anterior myocardial infarct size were
analyzed using a one-way ANOVA. ANOVAs were per-
formed using Statview v4.1 software (Abacus Concepts,
Berkeley, California). Among-group differences in inci-
dence of lethal ischemic arrhythmia were analyzed using a
Fisher exact test.
RESULTS
Table 1 summarizes the effects of vehicle, losartan,
EXP3174 and captopril treatment on heart rate, mean
arterial pressure and electrocardiographic intervals. Table 2
summarizes the effects of treatments on ventricular excit-
ability and refractoriness in posterolateral NZ and anterior
Table 1. Effect of Intravenous Losartan (1.0 mg/kg 1 0.03 mg/kg/min), EXP3174 (0.1 mg/kg 1 0.01 mg/kg/min), Captopril
(1.0 mg/kg 1 0.5 mg/kg/h) or Vehicle on Sinus Heart Rate, Mean Arterial Pressure and Electrocardiographic Intervals in
Postinfarction Dogs
Parameter
Vehicle
(n 5 9)
Losartan
(n 5 8)
EXP3174
(n 5 8)
Captopril
(n 5 10)
Pre Post Pre Post Pre Post Pre Post
Heart rate (beats/min) 124 6 4 120 6 4 121 6 4 128 6 5 122 6 5 122 6 6 115 6 3 120 6 4
Mean arterial pressure
(mm Hg)
54 6 2 55 6 4 47 6 2 36 6 4† 47 6 3 38 6 4† 54 6 3 40 6 4†
PR interval (ms) 108 6 5 105 6 5 105 6 5 102 6 5 104 6 5 107 6 5 107 6 6 103 6 4
QRS interval (ms) 49 6 1 49 6 1 49 6 1 48 6 1 46 6 2 48 6 2 49 6 2 51 6 1
QTc interval (msec/=s) 361 6 5 370 6 6 386 6 11 389 6 10 379 6 7 387 6 9 359 6 8 365 6 5
No values significant at *p , 0.05 level in Table; †p , 0.01 compared with appropriate “pre” value using a two-way analysis of variance comparing within treatment groups by
repeated measure as well as among all treatment groups followed by a within-group two-tailed paired Student t test.
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IZ. Neither the saline nor PEG/D5W vehicles altered these
parameters in individual subgroups; hence, these vehicle
data are grouped. In this chloralose-anesthetized postinfarc-
tion dog model, losartan, EXP3174 and captopril compa-
rably and significantly reduced mean arterial pressure by
23.7 6 5.1%, 20.3 6 3.8% and 25.9 6 5.4%, respectively
(Table 1). Sinus heart rate, electrocardiographic intervals
(Table 1) and NZ and IZ cardiac electrophysiologic param-
eters (Table 2) were not altered significantly by losartan,
EXP3174 or captopril.
Table 3 summarizes plasma renin activities in the vehicle,
losartan, EXP3174 and captopril treatment groups. Plasma
renin activities were elevated maximally 5.2- and 5.3-fold in
the captopril and losartan groups, respectively, and 3.2-fold
in the EXP3174 group. Plasma renin activity was elevated
maximally 1.6-fold in the vehicle control group. In the
losartan treatment group, mean plasma losartan and
EXP3174 concentrations were 13.1 mg/ml and 58 ng/ml,
respectively, at 1 h into the losartan infusion, and 14.2
mg/ml and 78 ng/ml, respectively, at 2 h into the losartan
infusion. Hence, the presence of EXP3174 in the losartan
group was minimal (,1%) compared with that of parent
losartan, indicating little metabolic conversion of losartan to
EXP3174 in the dog. In the EXP3174 treatment group,
mean plasma EXP3174 concentrations ranged between 4.8
and 6 mg/ml at 1 to 4 h into the EXP3174 infusion.
Table 4 summarizes the effects of vehicle, losartan,
EXP3174 and captopril treatments on arrhythmic response
to the development of secondary acute posterolateral myo-
cardial ischemia. Figure 1 depicts the time course for the
development of lethal ischemic arrhythmias after the devel-
opment of acute posterolateral ischemia for the four treat-
ment groups. Consistent with previous experience with this
preparation (17,24), the incidence of lethal arrhythmias in
the present vehicle control group was 7/9 (77%), with
mortality rates of 3/4 in saline control and 4/5 in PEG/
D5W control subgroups. All lethal arrhythmias in the
vehicle control animals were ventricular tachycardias degen-
erating into ventricular fibrillation. In both the losartan and
captopril groups, the incidences of lethal ischemic ventric-
ular arrhythmias, 6/8 (75%) and 7/10 (70%), respectively,
were comparable with that of the vehicle control group. All
Table 2. Effect of Intravenous Losartan (1.0 mg/kg 1 0.03 mg/kg/min), EXP3174 (0.1 mg/kg 1 0.01 mg/kg/min), Captopril
(1.0 mg/kg 1 0.5 mg/kg/h) or Vehicle on Cardiac Electrophysiologic Parameters in Postinfarction Dogs
Parameter
Vehicle
(n 5 9)
Losartan
(n 5 8)
EXP3174
(n 5 8)
Captopril
(n 5 10)
Pre Post Pre Post Pre Post Pre Post
Noninfarct Zone
Ventricular excitation
threshold (mA)
0.10 6 0.01 0.10 6 0.01 0.10 6 0.01 0.10 6 0.01 0.11 6 0.02 0.12 6 0.02 0.11 6 0.01 0.11 6 0.01
Ventricular relative
refractory period (ms)
170 6 6 176 6 6 180 6 3 186 6 4 177 6 2 180 6 3 166 6 4 173 6 5
Ventricular effective
refractory period (ms)
137 6 4 144 6 4 150 6 4 156 6 5 150 6 3 154 6 4 136 6 3 147 6 4
Infarct zone
Ventricular excitation
threshold (mA)
0.20 6 0.03 0.20 6 0.03 0.25 6 0.08 0.28 6 0.09 0.24 6 0.05 0.26 6 0.06 0.23 6 0.06 0.30 6 0.09
Ventricular relative
refractory period (ms)
168 6 5 172 6 4 165 6 9 165 6 9 180 6 6 180 6 7 159 6 7 163 6 7
Ventricular effective
refractory period (ms)
147 6 5 151 6 5 137 6 5 137 6 7 155 6 6 156 6 7 137 6 5 141 6 4
No values significant at *p , 0.05 or †p , 0.01 in Table compared with appropriate “pre” value using a two-way analysis of variance comparing within treatment groups by
repeated measure as well as among all treatment groups followed by a within-group two-tailed paired Student t test. Data are mean 6 SEM. Posttreatment measurements were
obtained at 1 h after initiation of IV bolus 1 infusion treatment.
Table 3. Plasma Renin Activities in Postinfarction Dogs Administered Intravenous Losartan (1.0 mg/kg 1 0.03 mg/kg/min),
EXP3174 (0.1 mg/kg 1 0.01 mg/kg/min), Captopril (1.0 mg/kg 1 0.5 mg/kg/h) or Vehicle
Time After
Initiation of
Treatment
Plasma Renin Activity (ng/ml/h)
Vehicle Losartan EXP3174 Captopril
Pretreatment 10.46 6 3.41 (n 5 8) 8.73 6 2.37 (n 5 8) 10.64 6 3.14 (n 5 8) 7.75 6 3.00 (n 5 10)
1 h 14.51 6 4.96 (n 5 8) 46.12 6 7.10 (n 5 8) 33.59 6 6.05 (n 5 8) 40.30 6 5.32 (n 5 9)
2 h 16.90 6 5.05 (n 5 8) 42.04 6 8.86 (n 5 8) 20.31 6 2.71 (n 5 8) 29.94 6 4.71 (n 5 8)
4 h 13.93 6 0.75 (n 5 2) 23.58 6 3.96 (n 5 2) 23.43 6 4.42 (n 5 6) 23.34 6 2.75 (n 5 3)
Data are mean 6 SEM.
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ischemic mortalities in the losartan and captopril groups
were ventricular tachycardias degenerating into ventricular
fibrillation. In contrast, the incidence of lethal ventricular
arrhythmias in the EXP3174 group, 2/8 (25%), was signif-
icantly (p , 0.05) lower than that of the vehicle control
group. Interestingly, one of the two arrhythmic mortalities
in the EXP3174 group was bradyarrhythmia and arrest,
while the second was ventricular tachycardia degenerating
into ventricular fibrillation. Times to onset of acute postero-
lateral myocardial ischemia were equivalent in the vehicle,
losartan, EXP3174 and captopril groups, suggesting no
significant treatment effect on the process of thrombotic
occlusion of the LCX coronary artery. Wet thrombus mass
determined at the site of LCX coronary artery electrolytic
lesion at the termination of the study, i.e., development of
lethal ischemic arrhythmia or at 3 h after onset of postero-
lateral myocardial ischemia in surviving animals, did not
differ significantly among the four treatment groups, again
suggesting no significant treatment effect on thrombus
formation. It is noteworthy that LCX thrombus mass
tended to be greater in the EXP3174 group compared with
the other treatment groups, reflecting the lower incidence of
sudden ischemic lethal arrhythmias and therefore greater
prevalence of animals in the EXP3174 group surviving to a
later time point in the protocol. Underlying anterior myo-
cardial infarct sizes did not vary significantly among the four
treatment groups. The similarity in underlying anterior
infarct sizes, particular in the losartan versus the EXP3174
treatment groups, precludes smaller infarcts and potentially
less vulnerable myocardial substrates as a cause for the lower
arrhythmic mortality in the EXP3174 treatment group.
DISCUSSION
The renin-angiotensin system is activated in experimental
animals and in humans after acute myocardial infarction
(25,26) and in heart failure (27,28). By virtue of its direct
positive inotropic, chronotropic and coronary vasoconstric-
tor actions, AII may promote ischemia in vulnerable myo-
cardium, potentially destabilizing cardiac rhythm (29). An-
giotensin II may further compromise the coronary oxygen
supply/demand balance, exacerbate local ischemia and pro-
mote arrhythmia by increasing sympathetic tone through
both a central effect as well as augmenting local (cardiac)
neuronal and adrenomedullary catecholamine release
(29,30). Angiotensin II also stimulates the expression and
release of endothelin, a highly potent vasoconstrictor and
arrhythmogenic cytokine, from endothelial cells (31,32).
Several studies have demonstrated direct cardiac electro-
physiologic effects of AII that may affect cardiac electrical
stability. In isolated cardiac myocytes, AII facilitated or
activated inward Ca21 (33), Na1 (34) and Cl2 currents (35)
and increased the rapidly activating component (IKr) but
decreased the slowly activating component (IKs) of outward
delayed rectifier K1 current (36), and altered the kinetics of
activation and inactivation of transient outward (Ito) K
1
current (37). In isolated rat ventricular muscle strips, AII
decreased refractoriness, an effect blocked by losartan (38).
In conscious pigs with surgically induced myocardial infarc-
tion, intravenous AII decreased ventricular refractoriness
and promoted electrically induced and spontaneous ventric-
ular arrhythmia (39). In isolated ventricular cell pairs from
Table 4. Effect of Intravenous Losartan (1.0 mg/kg 1 0.03 mg/kg/min), EXP3174 (0.1 mg/kg
1 0.01 mg/kg/min), Captopril (1.0 mg/kg 1 0.5 mg/kg/h) or Vehicle on the Incidence of
Lethal Ischemic Arrhythmias Developing in Response to Secondary Acute Posterolateral
Myocardial Ischemia in Postinfarction Dogs
Parameter
Vehicle
(n 5 9)
Losartan
(n 5 8)
EXP3174
(n 5 8)
Captopril
(n 5 10)
Incidence of lethal arrhythmias 7/9 6/8 2/8* 7/10
Time to ischemia (min) 59.7 6 9.4 60.0 6 5.4 55.6 6 12.2 50.2 6 9.3
Thrombus mass (mg) 3.8 6 0.8 5.2 6 1.6 7.6 6 3.1 3.8 6 1.1
Underlying anterior myocardial
infarct size (% of left ventricle)
28.1 6 2.4 23.8 6 4.9 23.1 6 3.4 25.5 6 3.5
*p , 0.05; no values significant at †p , 0.01 compared with vehicle control value using a one-way analysis of variance or Fisher
exact test as appropriate. Data are mean 6 SEM.
Figure 1. Survival of losartan (n 5 8; 1 mg/kg IV bolus 1 0.03
mg/kg/min continuous IV infusion), EXP3174 (n 5 8; 0.1 mg/kg
IV bolus 1 0.01 mg/kg/min continuous IV infusion), captopril
(n 5 10; 1 mg/kg IV bolus 1 0.5 mg/kg/h continuous IV infusion)
and vehicle-treated (n 5 9) dogs with previous anterior myocardial
infarction expressed as a function of time after onset of throm-
botically induced acute posterolateral myocardial ischemia.
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normal rat hearts, AII decreased junctional conductance, an
effect blocked by losartan (40). Similarly, in isolated ven-
tricular cell pairs from normal and cardiomyopathic hamster
hearts, AII decreased junctional conductance, and in the
latter tissues caused complete electrical uncoupling, an effect
reversed by losartan (41).
Antiarrhythmic efficacy of ACE inhibition and AII an-
tagonism. Given the multiple mechanisms by which AII
may influence cardiac electrical activity and stability, con-
siderable attention has focused on the potential for ACE
inhibitors to afford antiarrhythmic protection. Large mor-
tality trials with ACE inhibitors, however, have failed to
conclusively demonstrate a favorable effect on arrhythmic
mortality, and both clinical and in vivo preclinical studies
have failed to consistently demonstrate a significant reduc-
tion in the incidence of ventricular arrhythmia (9,10).
Interest in the antiarrhythmic potential of direct AII recep-
tor antagonism recently has been heightened by the results
of the Losartan Heart Failure Study ELITE. ELITE
compared therapy with the prototype AII antagonist losar-
tan with that of the ACE inhibitor captopril in patients
with chronic symptomatic heart failure, a patient group in
which ACE inhibitors including captopril have demon-
strated significant survival benefit (12). ELITE was a
722-patient trial primarily designed to assess effects on renal
function. Although no difference was observed in renal
function between treatment groups, and hemodynamic
status improved comparably in both treatment groups, an
unexpected survival benefit was observed in the losartan
group compared with the captopril group, with the lower
mortality in the losartan group largely confined to a reduc-
tion in sudden cardiac death (12).
Any consideration of in vivo pharmacologic actions of
losartan must include consideration of EXP3174, the active
carboxylic acid metabolite of losartan formed in humans.
Whereas losartan is a competitive, surmountable antagonist
of AII, EXP3174 is a noncompetitive, insurmountable
antagonist of AII with an intrinsic potency approximately
33-fold greater than that of losartan as determined by in
vitro antagonism of AII-mediated contraction of isolated
rabbit aortic strips (42). As noted previously, the present in
vivo intravenous dosing regimens of losartan, EXP3174 and
captopril were based on previous studies of these agents in
dogs (18-22), and were intended to elicit comparable
pharmacodynamic responses in this species. No attempt was
made to target human clinical plasma concentrations with
these dosing regimens. The formation of EXP3174 from
losartan is highly species dependent. In humans, the oral
bioavailability of losartan is 33%, with a time to peak plasma
concentration of 1 h, a plasma clearance of 610 ml/min, a
volume of distribution of 34 liters, and a terminal half-life of
2.1 h for parent compound (43). EXP3174 formed in
humans after oral losartan administration displays a time to
peak plasma concentration of 3.5 h, a plasma clearance of
47 ml/min, a volume of distribution of 10 liters and a
terminal half-life of 6.3 h (43). As a result of its much lower
plasma clearance, the AUC for EXP3174 formed after oral
losartan administration is approximately fourfold greater
than that of parent losartan, indicating EXP3174 to play an
important role in the pharmacodynamic activity and dura-
tion of action of losartan in man (43). The rat is also an
efficient metabolizer of losartan to EXP3174 (44). In
contrast, EXP3174 plasma levels have been reported to be
virtually undetectable after either intravenous or oral losar-
tan administration to dogs (45). Likewise, in the present
studies, the presence of EXP3174 in the losartan infusion
group was minimal (,1%) compared with that of parent
losartan. The dog, therefore, constitutes a useful species in
which to compare the cardiac electrophysiologic and anti-
arrhythmic effects of losartan and EXP3174 in the virtual
absence of metabolic conversion.
Preclinical antiarrhythmic assessments of losartan. Few
preclinical studies have assessed the cardiac electrophysi-
ologic and antiarrhythmic effects of losartan, and no studies
have simultaneously compared the antiarrhythmic activities
of losartan and EXP3174. In an in vitro guinea pig
ventricular wall preparation, losartan attenuated conduction
delays and decreased the incidence and duration of arrhyth-
mias during ischemic superfusion followed by reperfusion.
Paradoxically, AII also tended to attenuate conduction delay
during reperfusion and reduced the incidence of arrhythmia
in this preparation (13). During nonischemic superfusion,
losartan had no effects on cardiac conduction or refractori-
ness in the isolated guinea pig ventricular preparation (13).
Losartan also has been reported to have no effect on
junctional conductance in isolated ventricular cell pairs from
normal rat hearts (40). In spontaneously hypertensive rats
subjected to coronary artery occlusion and reperfusion, the
intravenous administration of losartan immediately before
coronary occlusion reduced the incidence of ischemic ven-
tricular fibrillation (14). However, losartan also reduced
developing myocardial infarct size in the latter study,
suggesting that arrhythmia suppression may have been
secondary to a reduction in severity of ischemia (14). In a
similar study in dogs subjected to coronary artery occlusion
and reperfusion, the intravenous infusion of losartan failed
to reduce the incidence of ventricular tachycardia or ven-
tricular fibrillation (15). There was no effect of losartan on
ventricular refractoriness or ECG QTc interval in dogs in
this study (15). A recent report describes the use of AII type
Ia knockout mice to assess the role of AII in cardiac
ischemia-reperfusion injury. When subjected to coronary
artery occlusion followed by reperfusion, a significant reduc-
tion in the incidence of ventricular arrhythmia was observed
in the angiotensin receptor knockout mice compared with
wild-type controls, despite no difference in the extent of
developing myocardial infarction (46). The latter observa-
tion suggests that AII may be an independent endogenous
inducer of arrhythmia during ischemic-reperfusion injury,
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and that direct antagonism of the AII receptor may be
useful in suppressing such arrhythmia (46).
Present studies. The present canine model of recent ante-
rior myocardial infarction (16) permits the assessment of the
potential of pharmacologic interventions to affect cardiac
electrophysiologic status of noninfarcted versus infarcted
myocardium and to suppress the development of lethal
ischemic ventricular arrhythmias. Susceptibility to the de-
velopment of lethal ischemic ventricular arrhythmias has
been shown to be strongly dependent on underlying anterior
myocardial infarct size. In an early characterization study, a
cohort of animals with an underlying anterior infarct size of
24.7 6 1.7% of the left ventricle displayed a significantly
higher incidence of lethal ischemic arrhythmias (73% and
93% incidence of lethal arrhythmias at 20 min and 24 h after
the onset of posterolateral ischemia, respectively) compared
with animals with an anterior infarct size of 5.3 6 1.1%
(13% incidence of lethal arrhythmias at both 20 min and
24 h after the onset of posterolateral ischemia) (47).
Underlying anterior infarct sizes observed in the present
treatment groups were comparable with that described for
high-risk animals in the earlier characterization study (47).
Further, the incidences of lethal ischemic arrhythmia in the
present vehicle, losartan and captopril treatment groups
were equivalent to that described for high-risk animals in
the characterization study above (47), as well as to previous
vehicle control group incidences of 80% to 85% in this
laboratory (17,24), indicating that the present postinfarction
dog model was at high risk for the development of ischemic
lethal ventricular arrhythmia. Losartan, EXP3174 and cap-
topril were infused in dosing regimens eliciting increases in
plasma renin activity and decreases in mean arterial pressure.
Quantitatively, the decreases in mean arterial pressure were
comparable among treatments, whereas the increase in
plasma renin activity achieved with EXP3174 was slightly
less than those achieved with the losartan and captopril
regimens. Electrocardiographic and cardiac electrophysi-
ologic determinations measured during test agent infusion
but before the onset of acute posterolateral myocardial
ischemia revealed no significant effects with losartan,
EXP3174 or captopril. Times to thrombotic occlusion of
the LCX coronary artery, used as a trigger for acute
posterolateral myocardial ischemia, as well as underlying
anterior myocardial infarct sizes, likewise were similar
among all treatment groups. The findings above indicate
that the significant reduction in the incidence of lethal
ischemic ventricular arrhythmias observed with EXP3174
but not losartan and captopril was not related to a suppres-
sion of peripheral vascular renin-angiotensin activity, pe-
ripheral hemodynamic activity or a direct cardiac electro-
physiologic effect before acute myocardial ischemia.
Local cardiac AII generation. One potential mechanism
for the suppression of lethal ischemic ventricular arrhyth-
mias with EXP3174 is an attenuation of a local adverse,
arrhythmogenic effect of AII released during the acute
myocardial ischemic trigger. Such a scenario, including the
superior efficacy of EXP3174 compared with captopril in
this study, is consistent with the existence and importance
of local ACE-independent, AII generation in the heart. For
example, it has been demonstrated that during acute myo-
cardial ischemia induced by left anterior descending coro-
nary artery occlusion in dogs, a greatly enhanced local
production and release of AII into the anterior interventric-
ular vein was inhibited by the serine protease inhibitor
nafamostat and by chymostatin, but not by captopril (21).
Sampling of cardiac interstitial fluid in dog heart has
demonstrated .100-fold higher local cardiac concentra-
tions of both angiotensin I (AI) and AII compared with
plasma values, with the local interstitial concentration of
AII insensitive to the intravascular administrations of both
AI and captopril, despite entry of captopril into the cardiac
interstitial compartment (22). These and other biochemical,
immunohistochemical and molecular biologic findings (re-
viewed in reference 22) have led to the understanding that
AII production and/or degradation in the intravascular and
local interstitial space of the heart are compartmentalized
and that AII generation in these compartments is mediated
by different enzymatic mechanisms, with cardiac interstitial
AII generated by a primarily ACE-independent pathway
(22). A recent study utilizing isolated human atrial muscle
strips has demonstrated AI-mediated tissue catecholamine
release to be potently inhibited by EXP3174, indicating the
catecholamine release to be due to local conversion of AI to
AII, but conversely, was insensitive to captopril reflecting
the functional significance of non-ACE-dependent AII
generation in human cardiac tissue (48).
Specificity and potential mechanism of antiarrhythmic
efficacy of EXP3174. An important implication of the
present study is that the antiarrhythmic efficacy displayed by
EXP3174 in this preparation may not be common to all AII
antagonists. Hypotheses addressing the superior antiar-
rhythmic efficacy of EXP3174 compared with losartan in
the present study are speculative at this time. These hypoth-
eses include the inherent nature of AII antagonism, i.e.,
noncompetitive insurmountable antagonism by EXP3174
versus competitive surmountable antagonism by losartan,
with noncompetitive insurmountable antagonism poten-
tially more efficacious in blocking the pro-ischemic and
pro-arrhythmic effects of excessive local cardiac AII. Tissue
compartment access also may differ for losartan and
EXP3174, and therefore may contribute to their differential
efficacies in this study. Finally, the existence of a non-AII-
related activity specific to EXP3174 underlying the superior
antiarrhythmic efficacy of this agent compared with losartan
and captopril cannot be precluded. Future studies are
required to further assess the relative antiarrhythmic activ-
ities of EXP3174 and losartan as well as other AII antag-
onists, and to explore the hypotheses noted above.
In summary, losartan’s noncompetitive AII antagonist
human metabolite EXP3174, but not the parent competi-
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tive AII antagonist losartan nor the ACE inhibitor capto-
pril, reduced the incidence of lethal ischemic arrhythmias in
a canine model of recent anterior myocardial infarction. The
antiarrhythmic efficacy of EXP3174 in this preparation was
unrelated to inhibition of the peripheral renin-angiotensin
activity and was not due to a direct cardiac electrophysi-
ologic effect occurring before the acute ischemic trigger.
These observations suggest that the antiarrhythmic efficacy
of EXP3174 may be due to an attenuation of deleterious
proarrhythmic effects of local cardiac AII formed during
acute myocardial ischemia, or alternatively, a non-AII-
related activity specific to EXP3174. These findings suggest
that in humans, metabolic conversion of losartan to
EXP3174 may impart antiarrhythmic protection superior to
that provided by an ACE inhibitor, consistent with the
findings of the Losartan Heart Failure Study ELITE (12).
A further corollary of these findings, particularly the supe-
rior activity of EXP3174 relative to losartan, is that the
antiarrhythmic efficacy displayed by EXP3174 in this prep-
aration may not be common to all AII antagonists.
Reprint requests and correspondence: Joseph J. Lynch, Jr.,
WP46-300, Merck Research Laboratories, West Point, Pennsyl-
vania 19486.
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